Sparsentan

(Filspari®)

Filspari®

Latest News

loading GIF

Drug updated on 4/16/2024

Dosage FormTablet (oral; 200 mg, 400 mg)
Drug ClassEndothelin and angiotensin II receptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Sparsentan (Filspari) is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.
  • Two studies focusing on the safety and effectiveness of Filspari in treating IgAN and Focal Segmental Glomerulosclerosis (FSGS) were analyzed.
  • One study addresses a broad population with IgAN, including both adults and children, emphasizing the need for non-immunosuppressive strategies across different age groups.
  • Antihypertensive agents such as RAS inhibitors are beneficial in reducing proteinuria with moderate certainty evidence but show little or no difference in rates of kidney failure or remission according to one study.
  • In terms of comparative effectiveness, antihypertensive treatments like RAS inhibitors show promise for reducing proteinuria, while other non-immunosuppressive therapies present mixed results, heavily influenced by subgroup characteristics such as those of Japanese patients with IgAN.
  • For steroid-resistant FSGS specifically, sparsentan may be considered an important treatment option due to its potential advantage over irbesartan in reducing proteinuria, though more robust evidence is needed before definitive conclusions can be drawn about its superiority.

Product Monograph / Prescribing Information

Document TitleYearSource
Filspari (sparsentan) Prescribing Information. 2023Travere Therapeutics, Inc., San Diego, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Non-immunosuppressive treatment for IgA nephropathy.2024The Cochrane Database of Systematic Reviews
Interventions for focal segmental glomerulosclerosis in adults. 2022The Cochrane Database of Systematic Reviews

Clinical Practice Guidelines

Document TitleYearSource
Practical considerations for the use of sparsentan in the treatment of patients with IgAN in clinical practice. 2023International Journal of Nephrology and Renovascular Disease